報價延遲最少15分鐘:2025/04/12 04:14 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.32 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.86/-0.87
|
|
企業價值
34.99M
|
| 資產負債 |
|
每股賬面淨值
-4.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 04:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. |